cyrilzakka/clinical-trials huggingface dataset:
Natural History of Hypereosinophilia and Hypereosinophilic Syndromes

Unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES) are heterogeneous regarding the organ involvements (heart, lungs, skin, .. or none), the evolutionary profiles, the response to treatments.

Underlying mechanisms are largely unknown and may associate genetic predisposing factors (germinal ? somatic?), environmental factors (alimentation, tobacco use, hormones, infections, ..) The COHESion study aims to study all clinical and biological characteristics of HE/HES patients and their evolutionary profiles, with a focus on genetic factors and the mechanisms supporting transitory or persistant chronic HE/HES (in absence of any well identified extrinsic trigger like drugs, parasitosis, ..)

There is currently no data on the natural history of unexplained chronic hypereosinophilia (HE) and hypereosinophilic syndromes (HES). Clinical practice shows that HE/SHE patients can present 4 evolutionary profiles:

A. a single flare-up of their disease, with favourable evolution spontaneously or under corticosteroid therapy, without further recurrence B. recurrent flare-ups with a variable free interval of several months to several years, with or without persistent eosinophilia between flare-ups C. a chronic disease requiring the continuation of a substantive treatment D. chronic asymptomatic HE for years: the mechanisms involved in the occurrence of possible organ damage are unknown

The primary objective of the study is to describe the frequency of the different clinical manifestations during the diagnostic and follow-up of the hypereosinophilic syndrome (HES). The primary endpoint is the frequency of the different clinical manifestations and/or organs damage related to eosinophilia.

Eligibility Criteria:
Inclusion Criteria:

* Men or Women of any age :
* With the diagnosis criteria of hyperosinophlia OR hypereosinophilic syndrome OR specific organ eosinophilic disease according to the consensus conference of the International Cooperative Working Group on Eosinophil Disorders (ICOG-EO)
* With an AEC \> 1500/mm3 or organ damage related to the presence of eosinophils in the tissues or organs whatever the context (idiopathic, clonal or reactive, including drug-related, parasitic or allergic)
* HES diagnosis since 2005/01/01
* Patients socially insured
* Patient who agreed to participate to the study, its proceedings and duration.

Exclusion Criteria:

* Known HIV infection
* Not socially insured
* Person unable to receive a enlighten information
* Person who refuse to sign the consent
* Persons deprived of their liberty
* Persons benefiting from a system of legal protection (tutelage / guardianship)
A New Monitor to Measure Dermal Blood Flow in Critically Ill Patients: a Preliminary Study

Background: Conditions of reduced perfusion are characterized by redistribution of blood flow away from the skin to more vital organs.

Study Objectives: To assess the efficacy of a non-invasive, dermal blood flow (DBF) monitor in detecting changes in perfusion in critically ill patients.

Preliminary Study

Study Population: critically ill patients in a general ICU

DBF, finger plethysmography and invasive mean arterial pressure (MAP) were recorded over an 8-hour period. DBF was measured using the I.S. MedTech DBF monitor, based on the hot-wire principle of thermal balance of a heater cooled by a moving medium, via a skin probe placed on the anterior chest wall. Sensitivity was evaluated by visual inspection during active states, either induced, e.g. fluid administration, or spontaneous, e.g. altered hemodynamics. Specificity was evaluated during stable states (minimal fluctuations of MAP and no active interventions applied or required). Data are expressed in terms of standard deviation (SD) and of the difference (SDD) between the MAP and each of the tested methods.

Eligibility Criteria:
Inclusion Criteria:

* All patients were ventilated and sedated during an 8-hour period of measurement

Exclusion Criteria:

* Age \< 18 years old
Vivio AS (Aortic Stenosis) Detection Study

Evaluate the sensitivity and specificity of the Vivio System when used as an aid in the identification of heart sounds associated with severe aortic stenosis.

Prospective, non-randomized, multi-center study of adult subjects referred for echocardiography. Total of 200 enrolled subjects at 3 sites. Up to 10 roll-in subjects per site. Enrolled subjects will undergo: Vivio data capture, Eko stethoscope capture of heart sounds, Standard of care transthoracic echocardiogram (TTE). Vivio analysis will not be available to non-Avicena personnel. Recorded sounds from the FDA-approved Eko stethoscope will be presented to an independent expert physician review panel blinded to Vivio and TTE results, to compare diagnosis of severe AS using Eko (auscultation) vs. Vivio (algorithms).

Eligibility Criteria:
Inclusion Criteria:

1. Adult subjects (21 years of age or older).
2. Referred for transthoracic echocardiography by physician/primary care provider/cardiologist.
3. Willing and able to participate in all study evaluations and allow access to medical testing and records.
4. Signed informed consent or have a legally authorized representative who provides informed consent on behalf of the subject.

Exclusion Criteria:

1. Acute coronary syndrome, cardiogenic shock or the need for inotropic/mechanical circulatory support.
2. Need for bedside echocardiogram (inpatient).
3. Prosthetic device previously implanted at aortic valve position.
4. Inability to palpate carotid pulse (e.g. due to severe obesity)
5. History of carotid sinus hypersensitivity (i.e. fainting in response to touching or positioning the neck).
6. History of carotid artery disease or treatment (e.g. unstable carotid plaques that might rupture upon massage or endarterectomy).
7. Open skin lesions at target site of electronic stethoscope/Vivio device examination.
Remove LPS Registry

This registry will collect and validate regulatory-grade real-world data (RWD) on the usage of the LPS-Adsorber and the outcomes from using the LPS-Adsorber in various patient populations (various sub-registries) that also have suspected endotoxemia. This data can be then used in real-world evidence (RWE) generation. It will also create reusable infrastructure to allow creation or affiliation with many additional RWD/RWE efforts both prospective and retrospective in nature.


Eligibility Criteria:
Inclusion Criteria:

* Weight \> 30 kilos

Specific sub-registry criteria are possible.

Exclusion Criteria:

* None
A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease

The purpose of this trial is to evaluate natalizumab in individuals with moderately to severely active Crohn's Disease.

Natalizumab is a humanized monoclonal antibody currently being investigated as a potential treatment for Crohn's disease. It is believed to work by preventing white blood cells from moving from the blood stream into the bowel tissue. These cells are thought to cause damage to the bowel, leading to the symptoms of Crohn's disease. Elan Pharmaceuticals is currently sponsoring an international study evaluating the safety and efficacy of natalizumab in individuals with moderately to severely active Crohn's disease. Individuals with Crohn's disease will be randomly assigned to receive either placebo (an inactive solution) or natalizumab by intravenous infusion (this means putting it directly into a vein in the arm). There will be a one out of two chance of receiving natalizumab and a one out of two chance of receiving placebo. Participants in the study will receive several infusions of natalizumab or placebo at 4-week intervals. Eligible participants will then have the opportunity to enroll into an extension study that will allow all participants to receive natalizumab. For those patients who do not enroll into the extension study, the total participation in this study will last for approximately 22 weeks.

Eligibility Criteria:
* Males and females 18 years of age or older
* Diagnosis of Crohn's disease for at least 6 months
* Females must not be pregnant or breastfeeding
* Must not have previously taken natalizumab
* Use of some other Crohn's disease medications is permitted, but will be closely supervised
OphtAI Diagnostic Performance Validation for Automated Screening of Eye Diseases

Evolucare OphtAI is a medical device offering automated, artificial intelligence powered, screening capabilities for Diabetic Retinopathy, Diabetic Macular Edema, Glaucoma, ARM and AMD, whose performances will by tested through the OphtAI-EVAL.

OphtAI-Eval: is a prospective, multicentre, post-marketing clinical follow-up study (SCAC) of diagnostic validation (comparative vs gold standard).

It aims to: validate the diagnostic performance of the OphtAI software for the automated screening of diabetic retinopathy, diabetic macular edema, glaucoma, ARM and AMD.

Evolucare OphtAI is a medical imaging console for ophthalmology, interfaced with Evolucare Imaging.

It allows the detection, by statistical learning algorithms, of the following ocular pathologies using photographs of the retina:

* Diabetic retinopathy (DR) (including gradation),
* Diabetic macular edema (DME)
* Age-related macular degeneration (AMD)
* Age-related maculopathy (ARM, early form of AMD),
* Glaucoma.

Evolucare OphtAI, is available on the French market since March 2019.

Eligibility Criteria:
Doesn't not accept healthy volunteers as diabetic patients are needed, still they may be free of any eye diseases.

Inclusion Criteria:

The characteristics required for a subject to take part in the research are

* Male or female over 18,
* Type 1 or 2 diabetic,
* Presenting for screening for diabetic retinopathy,
* Beneficiary of a social security scheme,
* For whom written consent has been obtained for participation in the protocol.

Exclusion Criteria:

The following characteristics do not allow the subject to take part in the research:

* Patient with known DR, more severe than "minimal", including having been treated,
* Any other condition that, in the opinion of the health professionals, may interfere with their ability to complete the study or may present a significant risk,
* Presence of social, medical and/or psychological factors that may compromise the patient's adherence to the protocol,
* Simultaneously participating in another clinical research protocol or having recently participated in another research study for which the exclusion period would not be completed.

Patients who participate in this research will not be able to participate in another research at the same time. However, there is no exclusion period at the end of this research for participation in any other study.
Effect of Presenting Survival Information as Text or Pictograph During Periviable Birth Counseling

Women recruited from the internet will be put in a hypothetical situation of being in labor at 22 weeks of pregnancy, and presented with information on the likelihood of survival and chance of disability for babies born at this gestational age.

Participants will be randomized to receive this outcome data in one of three formats: as text-only, in a static pictograph, or in an iterative pictograph. Participants will also be randomized to seeing the chance of survival as 30% or 60%.

Participants were then asked to choose between comfort care and intensive care in this situation. Participants' religiosity, value of the sanctity of life, and health literacy were also assessed.

A recent study by Kidszun et al. (2020) concluded that for mothers placed in a hypothetical situation of choosing between comfort care and intensive care at 22 weeks gestation, treatment choice was not influenced by the chance of survival. Specifically, there was no difference in treatment choice between moms who were told the baby would have a 30% chance of survival and moms who were told the baby would have a 60% chance of survival.

The study was conducted using a written vignette that included a paragraph on the chance of survival and the chance of disability among the survivors.

In this study, we will adapt the vignette the Kidszun et al. (2020) team used, and provide it to an internet-based sample of women. In this vignette, participants will be put in a hypothetical situation of being in labor at 22 weeks of pregnancy, provided a description of the treatment choices of intensive care or comfort care, and provided data on outcome information at this gestational age.

After reading the vignette, participants will be randomized to view either: a repeat of the text information on outcome data, a static pictograph, or an iterative pictograph. Participants will also be randomized to seeing the chance of survival as 30% or 60%, making this a 2 (chance of survival) x 3 (data presentation format) between-subjects experiment.

After viewing a repeat of the outcome information, participants will be asked to choose between intensive care or comfort care for their hypothetical child. We will also collect information on values, religiosity, health literacy, subjective numeracy, a subjective probability estimate, and demographics.

Eligibility Criteria:
Inclusion Criteria:

Women who have:

* had a child,
* are currently of child-bearing age (defined as 18-45)
* and who live in the U.S.

Exclusion Criteria:

* Minors
* Those unable to read English
* Those who only could complete the survey on their phone. (For formatting purposes, a tablet or computer is necessary.)
Sacroiliac Joint Dysfunction and Spinal Mobility in Women With Primary Dysmenorrhoea

Evaluation of sacroiliac joint dysfunction in young women with primary dysmenorrhoea using joint provocation and mobility tests and spinal mobility using Spinal Mouse and investigation of the relationship between primary dysmenorrhoea, sacroiliac joint dysfunction and spinal mobility.

Dysmenorrhoea is defined as pathological symptoms associated with menstruation, manifested by abdominal cramps and pain during menstruation and interfering with social life. The pain is of uterine origin and is one of the most common gynaecological disorders in women of childbearing age. It is divided into two types as primary dysmenorrhoea and secondary dysmenorrhoea.

Primary dysmenorrhoea is the most common form and is characterised by cramping pelvic pain that begins shortly before or at the onset of menstruation and lasts for one to three days. It usually begins during puberty and manifests itself with painful menstruation in women with normal pelvic anatomy.

Sacroiliac joint dysfunction is thought to be caused by different causes such as sacroiliac strain, sacroiliac instability and sacroiliac arthritis. One of the distinguishing features is local tenderness in the sacroiliac joint.

There are limited number of studies showing the relationship between sacroiliac joint dysfunction and menstrual cycle. Studies have shown that osteopathic manual therapy techniques applied to the pelvis are effective in alleviating the severity of primary dysmenorrhoea. At the same time, researchers have reported that mobilisation applied to the lumbopelvic regions is good for menstrual pain. Thus, it can be said that mobility is important in primary dysmenorrhoea.

Eligibility Criteria:
Inclusion Criteria:

* Being a woman between the ages of 18-24
* Being single
* Have a regular menstrual cycle (every 24-32 days)
* Duration of menstruation between 3-7 days
* Severity of primary dysmenorrhoea according to VAS

Exclusion Criteria:

* Refusal to participate
* Diagnosis as a patient with secondary dysmenorrhoea
* Presence of chronic disease
* Regular medication
* Polycystic ovary syndrome
* Pelvic inflammatory diseases
* History of uterine, cervical or ovarian cancer
* Previous gynaecological interventions
Neurological Impairment in a Young Population Exposed to Recreational Nitrous Oxide

Nitrous oxide (N2O) is a colorless, flammable, analgesic gas used in surgery and dentistry. The consumption of N2O has increased among young French people aiming to relax because of its short-lived neuropsychological effect (euphoria, depersonalization, analgesia) and its wide availability on the market.

It can be responsible in case of prolonged use and overdose of a vitamin B12 deficiency with possible neuropsychiatric complications: sensitivomotor neuropathy, myelopathy, behavioral and cognitive disorders of acute or sub-acute installation.

N2O inhibits the activitý of methionine synthase, decreases the activitý of methylmalonyl-CoA mutase leading to vitamin B12 deficiency but in addition to the interference with vitamin B12 metabolism there seems to be a direct toxicity of N20.

Myelin alteration was the typical electromyography finding but new axonal profiles were also described. Since myelopathy affects both the posterior and lateral cords, combined spinal cord sclerosis is the most common location of injury associated with N2O intoxication.


Eligibility Criteria:
patients presenting to the CHU of Nîmes with an acute or sub-acute neurological picture after having consumed N2O

-
Kisspeptin/GPR54 Pathway and Early Puberty

There was a worldwide early trend in girls'age for puberty onset. The timing of puberty onset varies greatly among individuals, and much of this variation is modulated by genetic factors. This study was designed to explored the association of polymorphisms in KISS1/GPR54 pathway genes and the risk of early puberty in Chinese Han girls.


Eligibility Criteria:
Inclusion Criteria:

- Clinical diagnosis of central precocious puberty or early and fast puberty.

Exclusion Criteria:

* The participants who were not the first visit to the hospital and had been treated before.
* The participants who were with endocrine disorders.
Evaluate the Accuracy of the NBM200 for Noninvasive Hemoglobin Measurements on Obstetric/Gynecological Patients

The purpose of the study is to define the precision, accuracy and variability of the NBM-200 system in non invasive blood Hemoglobin (Hb) measurements relative to the laboratory blood analyzer by comparing two consecutive Hb values obtained by the NBM system to venous values.

Each subject will be placed in a comfortable position in a temperature regulated room. Participants will have two consecutive non invasive (NBM) measurements taken which involves inserting the thumb into a ring shaped sensor. After each non invasive measurement the sensor will be removed. Each measurement takes approximately 85 seconds and involves the finger cuff inflating (to over systolic pressure) and deflating several times in quick successions in order to measure and calculate the Hb values. The two non invasive measurements will be performed using the same finger. After the NBM system testing is complete and recorded, the subject will have a venous (venipuncture) blood sample collected in order to provide two blood tests performed on two different models of routine automated CBC or Hb blood analyzers.

Eligibility Criteria:
Inclusion Criteria:

* Female volunteers aged 18 years and over.
* Any patient subject to CBC testing according to OBGYN standard care and clinical judgment.

Exclusion Criteria:

* Participants under the age of 18 years
* Significant deformity, degenerative changes or edema of the thumb or index fingers
* Localized infection, ulceration or skin breaks involving the fingers
* Low peripheral body temperature (tissue perfusion) \<36.0˚C
* Vascular disease or Raynaud's phenomenon affecting the fingers
* Participants who are unable to give informed written consent
Presurgical Language Mapping With fMRI: Comparison of BOLD and fASL Techniques

One of the aim of the neurosurgical treatment of brain tumor is to offer the maximal resection with the minimal neurological risk. The presurgical mapping of eloquent areas with functional magnetic resonance imaging (fMRI) is helpful to plan the surgery. BOLD fMRI is now the gold standard to map language areas. However, BOLD signal is diminished near the brain tumor. It is now possible to detect cortical activation with arterial spin labeling (ASL) techniques, detecting variations of perfusion during an activation paradigm (fASL), fASL could be interesting to detect eloquent areas near a brain tumor.


Eligibility Criteria:
Inclusion Criteria:

* Patient 18 years and older
* Brain tumor involving frontal and/or temporal lobe and/or insula, with scheduled neurosurgery
* Patient able of accepting protocol information
* Patient who received information about the protocol and had not expressed its opposition to participate

Exclusion Criteria:

* Patient with any surgical clip, external clips, or any other ferromagnetic device, that is contraindicated for use in MRI
* Claustrophobic patient
* Patients who cannot cooperate for the fMRI
* Patients subject to major legal protection (safeguarding justice, guardianship, trusteeship), persons deprived of liberty
Validation of Completion of Items 18, 19 and 22 of the Motor Function Measure (MFM) on a Digital Tablet

Motor Function Measure (MFM) is a validated tool assessing the motor function of neuromuscular patients constituted of 32 items. Despite standardized Motor Function Measure (MFM) training sessions, there is still an inter-individual variability in the items' scoring procedure, depending for example on the subjectivity of the therapist.

Among the 32 items of the MFM, 3 currently require the use of a paper, and could be automated by using a digital tablet. It is the item 18 where the patient traces the edge of a Compact Disc, item 19 requiring to draw loops inside a frame and item 22 requiring to place a finger on each standardized cases. The reproducibility of these 3 items could be improved with the use of a digital tablet and the development of a software allowing to computerize the scoring procedure. The second interest is to implement directly the MFM data in the MFM base.

The hypothesis is that the difference of scoring of these 3 items between digital tablet versus paper completion is enough low to use indifferently each completion in patients with a neuromuscular disease.


Eligibility Criteria:
Inclusion Criteria:

* Patients with a labelled neuromuscular disease
* Patients with Motor Function Measure in one of the participating services during their usual follow-up
* Patients who received the information and did not object to participating in the study or their parents for the children

Exclusion Criteria:

* Patients passing their Motor Function Measure as part of another research protocol
Integrated Neuromuscular Inhibition Versus Cervical and Scapular Stabilization Exercises on Myofascial Trigger Points of Upper Trapezius

This trial will involve three groups. The Integrated Neuromuscular Inhibition group will receive the integrated neuromuscular inhibition technique. The cervical and Scapular stabilization group will receive cervical and scapular stabilization exercises. The ultrasound group will receive ultrasound therapy


Eligibility Criteria:
Inclusion Criteria:

* Patients with active trigger points in the upper trapezius for more than 2 weeks based on the Simons Criteria.
* Age ranged from 18-25 years.
* Pain intensity ≥ 3 on VAS.
* Females and males.

Exclusion Criteria:

* Patients indicated for surgery.
* Patients with symptomatic disc lesions.
* Patients with rheumatological diseases or traumatic neck injury.
* Patients injected with corticosteroids in the last 6 months.